دورية أكاديمية

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades

التفاصيل البيبلوغرافية
العنوان: Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
المؤلفون: Weiping Liu, Xinqiang Ji, Yuqin Song, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Yingli Sun, Tingting Du, Jun Zhu
المصدر: Cancer Medicine, Vol 9, Iss 11, Pp 3765-3774 (2020)
بيانات النشر: Wiley, 2020.
سنة النشر: 2020
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Hodgkin disease, lymphoma, non‐Hodgkin, prognosis, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China. Methods A total of 3840 consecutive patients with lymphoma diagnosed between 1996 and 2015 were reviewed. Eighty patients were excluded, and finally, 3760 patients were analyzed in this study. The cohort was divided into four groups according to calendar periods at diagnosis: 1996‐2000, 2001‐2005, 2006‐2010, and 2010‐2015. The overall survival (OS) rates among the four groups were compared. Results The 5‐ and 10‐year OS for the whole cohort were 62% and 52%, respectively. The 5‐year OS of patient with classic Hodgkin lymphoma (cHL), mature B‐cell lymphoma (BCL), and peripheral T‐cell lymphoma (PTCL) were 79%, 63%, and 50%, respectively. Among mature BCL, the 5‐year OS was highest in follicular lymphoma (77.8%), followed by Burkitt lymphoma (76.5%), marginal zone lymphoma (74.1%), diffuse large B‐cell lymphoma (61.5%), small lymphocytic lymphoma/chronic lymphocytic leukemia (55.1%), and mantle cell lymphoma (44.3%). Among PTCL, the 5‐year OS was highest in ALK+anaplastic large cell lymphoma (79.0%), followed by ALK−anaplastic large cell lymphoma (63.1%), natural killer/T‐cell lymphoma (57.7%), angioimmunoblastic T‐cell lymphoma (34.9%, and peripheral T‐cell lymphoma not otherwise specified (27.6%). Significant improvement in the survival of lymphoma was observed, with the 5‐year OS increasing from 48% in 1996‐2000 to 65% in 2011‐2015 (P
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2045-7634
Relation: https://doaj.org/toc/2045-7634
DOI: 10.1002/cam4.3037
URL الوصول: https://doaj.org/article/0df58d9410af481ea37a5eb1f5839b97
رقم الأكسشن: edsdoj.0df58d9410af481ea37a5eb1f5839b97
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20457634
DOI:10.1002/cam4.3037